Bulk-Modified Elastomer for Homogeneous Cell Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing fluidic devices for in-vitro testing of mammalian cells face challenges in stabilizing and maintaining cell viability due to issues with biocompatible membrane manufacturing, non-homogeneous binding sites, and complex, costly microfabrication processes, which affect the reliability and efficiency of drug testing.
Innovation Solution
A biocompatible fluidic device is manufactured using a simplified process involving a single-step injection molding of an elastomer modified with fatty acid moieties, ensuring a homogeneous distribution of carboxylic acid groups for binding cell-culturing proteins, facilitating stable cell culture and drug testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a polymer coating with carboxylic acid groups is used to stabilize mammalian cells, then cell stabilization is improved, but the polymer is partially removed by fluid streams compromising evaluation reliability
Solution Approach 1:
The patent uses a composite material consisting of an elastomer matrix combined with cross-linkable moieties (such as silane groups) that provide carboxylic acid functionality. This composite structure integrates the stabilizing function directly into the membrane material rather than using a separate polymer coating, eliminating the problem of coating removal while maintaining cell stabilization capability
Solution Approach 2:
The invention extracts the carboxylic acid groups from a separate polymer coating and incorporates them directly into the elastomer membrane structure through cross-linking chemistry. This eliminates the need for a distinct coating layer that can be removed by fluid streams, while preserving the cell-stabilizing function
2Reliability
If UV or plasma treatment is applied to generate binding sites for fibronectin, then cell stabilization is improved, but inhomogeneous distribution of binding sites occurs hampering result evaluation
Solution Approach 1:
The patent changes the method of creating binding sites from surface treatment (UV/plasma) to a chemical cross-linking process that occurs throughout the membrane material. The cross-linking reaction between elastomer moieties and fibronectin is controlled through chemical parameters (pH, temperature, cross-linker concentration) to ensure uniform distribution of binding sites across the entire membrane surface
Solution Approach 2:
The invention introduces cross-linkable moieties (such as silane groups) as intermediaries that facilitate uniform chemical bonding between the elastomer membrane and fibronectin. These moieties provide consistent reaction sites throughout the material, enabling homogeneous distribution of binding sites without the variability introduced by UV or plasma treatment
3Reliability
If thin-film technology is used to manufacture biocompatible membranes, then cell stabilization is improved, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The patent merges the membrane structure and the cell-stabilizing function into a single integrated component. The elastomer membrane itself contains cross-linkable moieties that directly bind fibronectin, eliminating the need for separate thin-film coating processes and complex multi-layer structures while maintaining biocompatibility and cell stabilization capability
Solution Approach 2:
The elastomer membrane is designed to self-stabilize cells through its inherent cross-linkable moieties that can directly bind fibronectin without requiring external coating processes. The material performs its own functionalization, eliminating the need for separate manufacturing steps and reducing overall process complexity
4Adaptability or versatility
If cell-sized holes with small pitch are created in the membrane, then cell growth is facilitated, but manufacturing difficulty increases
Solution Approach 1:
The patent employs a porous elastomer structure where the porosity is integrated into the base material rather than requiring post-manufacturing hole creation. The cross-linking process and fibronectin binding occur throughout the porous matrix, allowing cells to grow within the three-dimensional pore structure without requiring precise small-pitch hole patterns
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a robust, cost-effective, and reliable fluidic device with homogeneous protein distribution, enabling prolonged cell viability and simplified manufacturing, enhancing the accuracy and efficiency of drug testing.
Implementation Method 1
the polymer having carboxylic acid groups, as such groups can (covalently) bond to the fibronectin
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A material for binding to a cell culturing protein is disclosed. The material contains a bulk-modified elastomer comprising a plurality of fatty acid moieties covalently bound to the elastomer bulk, wherein the carboxylic acid groups of said moieties are available to provide said binding. Also disclosed are a fluidic device module, a cell culturing scaffold, a fluidic device, the method of synthesizing such a material and a drug testing method. With such a material, a (monolithic) fluidic device module may be manufactured in as few as a single step injection molding process.